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Background: The recurrence rate after aneurysmal bone cyst (ABC) treatment is quite high despite its benign
nature. In ABC therapy, curettage is the treatment of choice; en bloc excision results in a lower recurrence rate, but
more extensive reconstructive surgery is needed with associated morbidity. The aim of the present study was to
compare the outcomes of the two treatment options.
Methods: A retrospective analysis was performed on 26 patients treated for ABCs: 16 by curettage and 10 by en
bloc excision. Each lesion was classified according to Enneking and patients were followed up for a mean time of
9.2 years. On follow-up, radiological examination and functional assessment (range of motion, muscle strength) were
performed. Recurrence was defined as the presence of an osteolytic lesion, especially one with a tendency to grow.
Results: On follow-up, the following symptoms were more prevalent in the en bloc excision group compared to the
curettage group: pain (en bloc 20% versus curettage 6.25%), limb length differences (en bloc 20% versus curettage
12.5%), reduced range of motion (en bloc 20% versus curettage 6.25%) and muscle strength impairment (en bloc 50%
versus curettage 31.2%); however, the differences were not statistically significant (P >0.05). In the curettage group, two
cases of postoperative complications and two cases of recurrence were seen, while in the en bloc excision group one
case of complications was noted.
Conclusions: Curettage is a standard procedure in ABC management. En bloc excision is another option, albeit more
technically demanding, that may be considered in recurrent lesions with extensive bone destruction or for cysts in an
expendable location.
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An aneurysmal bone cyst (ABC) is an expansile bone le-
sion that most commonly occurs in children and adoles-
cents. In contrast to simple bone cysts, aneurysmal cysts
seem to be benign neoplastic lesions with oncogene
(ubiquitin C-terminal hydrolase 6 (USP6), cadherin 11
(CDH11)) and insulin growth factor activity [1-3]. Despite
their benign nature, the recurrence rate of ABCs ranges
from 10% to 40% [4,5]. Cyst wall curettage with or without
adjuvant therapy is the treatment of choice for ABCs
[6-8]. Most authors recommend curettage in the case of* Correspondence: flont2002@yahoo.com
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reproduction in any medium, provided the orprimary cysts and reserve excision only for recurrent
cases, or for lesions located in expendable bones that can
be removed surgically without the need for bone recon-
struction [9-11]. Curettage is a fairly simple procedure that
usually encourages relatively fast recovery, while en bloc
excision result in a lower recurrence rate but more exten-
sive reconstructive surgery is needed, with associated mor-
bidity [5,9]. The purpose of this study was to report and
compare outcomes of pediatric ABC treatment via curet-
tage or en bloc excision.Methods
A retrospective analysis was performed on 26 patients
referred to our clinic for ABC treatment from 1993 to
2008. The following study inclusion criteria applied:td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographics, radiological type and clinical
outcomes by treatment group
Procedures Curettage En bloc
excision
Total
Sample size 16 10 26
Demographics:
Age range at diagnosis, years 2 to 18 9 to 16 2 to 18
Mean age, years 12.69 13.3 12.92
Median age, years 14 14 14
Female, % 62.5 50 57.69
Male, % 37.5 50 42.31
Radiological type:
Central/subperiosteal lesion 9/7 9/1 18/8
Enneking’s scale I/II/III II 9, III 7 I 1, II 3, III 6 I 1, II 12, III 13
Clinical outcomes:
Pain, % 6.25 20 11.54




Muscle strength impairment, % 31.2 50 38.46
Recurrences, n 2 0 2
Complications, n 2 1 3
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treated with one of the two surgical modalities to be
studied (cyst wall curettage or en bloc excision), surgical
procedure performed at the study site, and ABC con-
firmed by pathology and X-ray/computed tomography
(CT) (Philips Brilliance iCT 256®, Cleveland, Ohio,
USA). Patients with secondary ABCs confirmed by mag-
netic resonance imaging (MRI) (Picker Edge 1.5T® and
Philips Achieva 3.0T TX®, Cleveland, Ohio, USA) and
pathology, cysts treated with other methods, or cysts lo-
cated in the spine or the skull were excluded from the
study. In cases where X-ray/CT, location of the lesion,
patient age or clinical findings were not characteristic of
an ABC, an open biopsy and MRI examination were
performed to exclude such other conditions as giant cell
tumor, telangiectatic osteosarcoma, low-grade osteosar-
coma, chondroblastoma, osteoblastoma, angioma, fi-
brous dysplasia, chondromyxoid fibroma, non-ossifying
fibroma, unicameral bone cyst and eosinophilic granu-
loma [10]. Tissue obtained during the procedure was
evaluated histologically, and the following inclusion cri-
teria for ABC (as described by Lin et al.) were applied:
presence of blood-filled spaces, membranes composed of
spindle-shaped mononuclear stroma cells, lack of orga-
nization in stroma cells, osteoclast-like giant cells
scattered throughout the lesion, focal concentrated ag-
gregates of giant cells, absence of chondroid matrix and
plump mononuclear cells typical of giant cell tumors [6].
Typical MRI findings were internal septation, fluid-fluid
level formation and rim over the external surface of the
cyst (with possible focal break) [10]. In cases where
MRI/CT examination showed a solid or calcified area,
an open biopsy of the suspected area was performed to
exclude secondary lesions.
The demographic data of the subjects enrolled for the
study is shown in Table 1. Osseous locations were as fol-
lows: the fibula in eight patients (five in the proximal
and three in the distal metaphysis), the femur in six (two
in the subtrochanteric area, two in the distal metaphysis,
one in the lateral condyle and one in the shaft), the tibia
in four (two in the distal and one in the proximal
metaphysis and one in the shaft), the humerus in two
(one in the shaft and one in the proximal metaphysis),
the radius in two (shaft), and the scapula (lateral border),
the acromial end of the clavicle, the wing of ilium and the
shaft of the fourth metacarpal bone in one patient each.
Each ABC was categorized, firstly according to
Enneking’s scale for benign tumors (one of latent, active
or aggressive [12]), and secondly by location: central or
subperiosteal [9]. The mean follow-up period was 9.2
years from the surgery (range: 3 to 19 years). Outcomes
were evaluated radiographically using X-ray images of
the affected limb in standard positions [13] and by func-
tional assessments using bilateral measurements of rangeof motion and maximal muscle strength. The evaluation
also included measures of patient-reported outcomes.
Recurrence was defined as a radiologically-confirmed
osteolytic lesion, especially if the lesion displayed a ten-
dency to grow. In this event, the patient underwent a
second surgical procedure.
Range of motion (ROM) in the joint closest to the le-
sion was evaluated by standard goniometric assessment
[14,15]. All tests were performed bilaterally for compari-
son. A difference in ROM of more than 20% between
sides was considered clinically significant. Limb length
was assessed according to AO Foundation guidelines: a
1.5 cm difference for the lower limbs and a 2-cm differ-
ence for the upper limbs were considered significant [15].
Maximum isometric muscle force was measured in stand-
ard positions in two ROM planes using a calibrated hand-
held dynamometer (Advanced Force Gauge, Mecmesin®,
Slinfold, West Sussex, UK) and a difference of more than
20% between sides in at least one plane was considered
clinically significant [16,17]. The Pediatric Orthopedic
Society of North America (POSNA) pediatric musculo-
skeletal functional health questionnaire was used to evalu-
ate the patient reported outcomes [18,19]: the results were
reviewed based on the assumption that the cut-off point
of the patients’ wellbeing was the 25th centile.
Of the 26 patients who met the study inclusion criteria,
14 underwent cyst wall curettage, 10 en bloc excision and
2 curettage followed by en bloc excision (recurrence
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the operating surgeon and was based on the site, imaging
aspect and the preferences of the parent(s). In nine cases,
en bloc excision was performed on the central lesion with
extensive bone destruction, while in one case, in an
Enneking’s stage III subperiosteal lesion, the procedure
was performed in the radius shaft. In the curettage group
(n = 16), seven ABC cases were subperiosteal while nine
were central. In 15 of 16 cyst curettage procedures, the re-
section cavity was filled with bone grafts: 11 with freeze-
dried bone allografts and 4 with cortical cancellous bone
autografts harvested from the fibula or tibia. Each curet-
tage was performed with the use of a bone curette and a
high-speed burr. The adequacy of curettage was ascer-
tained by direct vision and the procedure was performed
until normal looking bone marrow was seen. In cases
where part of the ABC was close to the epiphyseal plate or
articular cartilage, only a bone curette was used under
direct vision. En bloc cyst excision was performed in 12
patients, mainly in central lesions: it was used as the pri-
mary procedure in 10 patients and treatment for recur-
rence after curettage in 2. In six cases, resection cavities
were filled with non-vascular fibular or tibial autografts
(Figure 1). Bone grafts were not used in cases involving
resection of expendable bones such as parts of the iliac
crest, the acromial end of the clavicle, diaphysis and prox-
imal metaphysis of the fibula. In one subperiosteal cyst
where the postexcisional bone mass was large enough to
provide a support function, bone grafting was not
performed.
The χ2 independence test was used to compare various
qualitative parameters in study groups and subgroups
selected on the basis of different variables: the Yates cor-
rection was used for small samples. As most of the param-
eters analyzed in the study were not normally distributed,
their means were compared using non-parametric tests:
the Mann–Whitney test (for two groups) and the Kruskal-
Wallis test (for several independent groups). The study
was approved by our Institutional Review Board (date of
issue 09.06.2009; registration number RNN/519/09/KB).
Results
At diagnosis, symptoms were present in 17 patients
(65.4%), and included pain at the affected site (n = 13), lo-
calized soft tissue edema (n = 3) and limping (n = 1). The
mean time from onset of symptoms to diagnosis and treat-
ment was 21 weeks (range 1 to 52 weeks). Only five sub-
jects (19.2%) presented initially with pathological fractures:
two with fibular cysts and individual patients with humeral,
scapular and radial cysts. All pathological fractures oc-
curred after low-energy trauma and were non-dislocated.
With regard to Enneking classifications, the majority of
ABCs were stage III (benign aggressive) (n = 13), followed
by stage II (benign active) (n = 12) and stage I (benignlatent) (n = 1). To evaluate treatment outcomes, the pa-
tients were divided into groups by type of primary proced-
ure. Group I were patients (n = 16) who underwent cyst
curettage, group II were patients (n = 10) who underwent
cyst en bloc resection. No statistically significant differ-
ences in age (z = 0.378; P >0.05) or sex (χ2 = 0.394; P >
0.05) were found between the treatment groups. Table 1
presents the demographics, radiological type and clinical
outcome data according to treatment group.
On follow-up, the following symptoms were more
prevalent in the en bloc excision group compared to the
curettage group: pain (en bloc 20% versus curettage
6.25%), limb length discrepancy (en bloc 20% versus cur-
ettage 12.5%), decreased ROM (en bloc 20% versus cur-
ettage 6.25%) and muscle strength impairment (en bloc
50% versus curettage 31.2%), but these differences were
not statistically significant (P >0.05). Moreover, no
intergroup differences were found in patient-reported
outcomes (P >0.05). The POSNA survey revealed that
out of the entire group of ABC cases, sport performance
impairment (73.1% of the whole study) was most com-
monly experienced symptom, followed by decreased
happiness (11.6%), increased sensation of pain (7.7%),
impaired upper extremity function (3.8%) and impaired
transfer and basic mobility (3.8%).
Only three patients in the whole study population
(two in the curettage group and one in the en bloc re-
section group) developed serious postoperative compli-
cations. These are outlined below.
The first patient experienced soft tissue inflammation
related to ABC in the proximal tibia metaphysis after
curettage with freeze-dried bone allografts requiring
reoperation, debridement of the inflammatory lesion and
implantation of a gentamicin-collagen sponge. The cause
of the inflammation remained undetermined as the cul-
tures came back negative. However, the inflammation re-
solved itself after debridement and the graft became
incorporated and consolidated completely, with full
function of the limb being restored.
The second patient experienced valgus deformity
(10 degrees) in the area of the distal femoral metaphysis,
associated with iatrogenic epiphyseal plate damage during
curettage or with direct cyst compression on the plate.
The patient, a boy, was 13 years old at the time of surgery.
The slight valgus deformity was noticed a year after the
operation and increased to 10 degrees, measured from the
mechanical axis on a weight-bearing radiograph, by the age
of 16. The parents and the patient were informed of the
possibility to perform an osteotomy but refused surgery.
The final patient experienced lateral instability of the
knee joint after excision of the proximal part of the fib-
ula. The patient reported lateral knee pain on exertion
and a feeling of knee instability when not wearing a
brace, but without functional limitation. The patient is
Figure 1 Example of a patient with an aneurysmal bone cyst (ABC) in the humerus treated with en bloc excision of the affected bone
fragment and autogenous fibular graft reconstruction. (A) Preoperative X-ray of the lesion; (B) X-ray follow-up directly after the surgical
procedure; (C) at 3 months postoperatively; (D) at 6 months postoperatively; and (E) final result, 3 years postoperatively. The ABC is healed with
small cystic lesions.
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after completion of skeletal growth.
With regard to treatment complications, two cases of
postoperative complications and two recurrence cases
were seen in the curettage group (n = 16) whereas one
case of postoperative complication was noted in the en
bloc excision group.
No pathological fractures were observed in the study
group in the course of treatment. The cyst relapsed in
two patients, both in the curettage group. The first case,a 15-year-old patient with distal tibial metaphysis ABC
experienced a recurrence about 18 months after surgery.
In the second case, the relapse occurred approximately 6
months postoperatively in a 2-year-old patient with a
distal fibular metaphysic cyst; the two recurrent lesions
were treated by resection of the entire affected bone
fragment with concurrent implantation of non-vascular
fibular autograft. All cysts that recurred were classed as
Enneking’s stage III: benign aggressive tumors. No local
recurrences were observed at Enneking’s stage I and II.
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Curettage remains the current standard of ABC treatment
[6-8]. Some authors also report use of en bloc excision but
use it only for expendable locations or in the event of mul-
tiple recurrences [5,9]. Alternative treatment via radiother-
apy has been used in the past, but due to the possible
induction of malignancy it is no longer employed [9,20].
Embolization [21,22] or sclerotherapy [23-25] seems a
valid alternative to surgery, especially in ABC cases of the
axial skeleton (spine, sacrum, pelvis) where surgery is con-
traindicated, especially in inaccessible lesions. Emboliza-
tion may be a primary treatment in lesions with substantial
soft tissue expansion in the proximity of neurovascular
structures such as the spine, or in large lesions to minimize
intraoperative hemorrhage, for example, in the pelvis
[21,22,26]. Recent advances in ABC treatment also include
curettage with an adjuvant such as phenol, hydrogen per-
oxide, liquid nitrogen, poly(methyl methacrylate) or argon
beam, which results in a reduced recurrence rate by broad-
ening the zone of tissue necrosis to include possible re-
sidual microscopic tumor cells [11,27-32].
The demographics of our group were not markedly
different from that of previous epidemiologic studies;
the age of the group in the present study is 12.9 years,
versus 11.1 [33] or 13 [34] years in others. The sex distri-
bution in our study was typical, and comparable to that
presented in a previous meta-analysis; the male/female ra-
tio of our group is 42.3%/57.7% versus 46.9%/53.1% of
Shreuder et al.’s meta-analysis [31].
Clinical presentation
Previous studies have shown pain (in 93% to 65% of
cases) and swelling (in 15 to 18.1%) to be associated with
ABCs at diagnosis. Palpable tumor and joint contracture
are less frequent (8%) and the prevalence of pathological
fracture varies from 3.4% to 25.9% [5,10,31]. In the
present study, the frequency of pain (50%) and local
edema (11.5%) were found to be lower. Such an under-
representation of patients reporting pain and edema in
our study may result from the fact that our cohort
consisted only of children, and hence the data was par-
tially obtained from medical histories taken mainly from
parents, which may not reflect the actual condition of
the patient. In our group, the time from onset of symp-
toms to treatment (21 weeks) is comparable with that seen
in other studies (14 weeks [5], 24 weeks [10], 27 weeks
[35]). A similar delay in ABC diagnosis in our patients im-
plies that the disease stage was similar, and therefore en-
ables the rates of recurrence and complications to be
compared with those of the literature data.
Bone growth impairment
Most authors do not discuss bone growth impairment
after surgical treatment of ABCs because the studypopulations include children and patients with completed
skeletal growth. In our study, four patients (15.5.%) devel-
oped bone growth impairment. The mean age of these
subjects at the time of procedure is comparable with that
of the group with normal limb development: 12.2 years
and 13 years. However, in all those patients, the cysts were
directly adjacent to the growth plate. Lin et al. noted only
a 5.3% rate of growth abnormalities that cause limb short-
ening and axis deviation. The authors suggest an associ-
ation between growth impairment and cyst recurrence
and damage to the growth plate during surgery [6].
Ramírez and Stanton noted a slightly higher percentage
of shortenings, 7.5% of patients (n = 3), and suggest on
the basis of MRI results that damage to the growth
plate caused by the cyst is directly responsible for growth
impairment [35].
Recurrences
In a retrospective study evaluating 185 patients,
Campanacci et al. found that the time to recurrence for
ABCs was 2 to 72 months [9]. Similarly, Ramírez and
Stanton reported that the mean time to recurrence was
18.7 months (range: 4 to 39 months) [35]. In our study,
the minimum follow-up period of 3 years seems suffi-
cient to reliably assess recurrence.
Vergel de Dios et al. reported a 21.8% recurrence rate
after curettage and did not note any relapses in patients
with en bloc excision. A total of 90% of recurrences oc-
curred in subjects below 20 years of age, and the mean
age of the patients with treatment failure was lower than
the mean age of the whole group (13.1 versus 16.1). The
authors associated recurrence with younger age, but the
statistical analysis did not confirm this [10]. In our study
group, the mean age of patients (12.9 years) is compar-
able to that of the patients with recurrences in the study
by Vergel de Dios et al. (13.1 years), but no greater fre-
quency of treatment failures was observed. The authors
also suggest that recurrences are associated with the cyst
being located in long bones, and that a more favorable
prognosis is associated with flat bones. They consider le-
sion curettage the treatment of choice for ABCs; they
state en bloc excision should only be used for lesions in
locations enabling affected site resection without func-
tional limitation [10].
Ramírez and Stanton also noted a 27.5% recurrence
rate after ABC treatment, as well as a halving of recur-
rence rate (from 40% to 21%) after the introduction of a
high-speed burr. As 75% of recurrences were seen in
children below 5 years of age, the authors hypothesize
that ABCs occurring in this age group display a more
aggressive evolution. Ramírez and Stanton also suggest
that unsatisfactory treatment results may be associated
with fear on the part of the surgeon of damaging the
growth plate in younger patients [35]. According to
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is as high as 21%. Relapses were more common in active
(25%) and aggressive (26%) lesions, but absent in cases
of curettage of inactive cysts and after en bloc excision.
Considering those findings, Campanacci et al. proposed
deeper curettage with addition of phenol or cryotherapy
in the treatment of more aggressive cysts. Bone excision
was also recommended as the treatment of choice when
the cyst is located in the proximal part of the fibula, dis-
tal part of the ulna, in ribs, pubic bone rami, and meta-
tarsal and metacarpal bones [9]. Gibbs et al. reported a
statistically significant correlation between the younger
age of the patient, the presence of open growth plates
and a higher rate of recurrences. While relapses oc-
curred in four patients (12%) aged 3, 4, 10 and 11 years
in the curettage group, no such cases occurred in pa-
tients treated with en bloc excision. As noted previously,
the authors link higher risks of recurrence to more ag-
gressive lesion types or insufficient excision of the
pathological tissue in the growth plate area. On the basis
of their own experience and the literature, Gibbs et al.
hypothesized that the use of additional chemical or
physical resection does not result in improved treatment
outcomes [5].
Lin et al. reported an 18.9% recurrence rate is associ-
ated with curettage. The cysts recurred significantly
more often in patients aged <12 years and in cases when
lesions were directly adjacent to the growth plate or ar-
ticular cartilage [6].
Similarly, the recurrence rates after curettage and en
bloc excision determined by Mankin et al., 22% and 5%,
respectively, were higher than in those found in the
present study. The authors saw a higher recurrence rate
in children below 10 years of age (24%), but the correla-
tions were not statistically significant. Furthermore, the
study indicated a higher recurrence rate for cysts located
in the clavicle (50%) or in the distal femur (46%), but
this suggestion was based only on a few cases. Out of
150 patients participating in their study, 34 were
reoperated, and 11 underwent 3 surgeries. The authors
recommend curettage as a treatment of choice and en
bloc excision of cysts of the femur, clavicle, foot bones,
scapula and fibula [11].
Schreuder et al. demonstrated the efficacy of add-
itional chemical resection in ABC surgery and recorded
a recurrence rate lower than in our findings (3.7%). The
burred surface was covered with sprayed liquid nitrogen
several times during the procedure, which allowed the
margin of bone excision to be extended without being
weakened and forestalling the need for reconstructive
surgery. No postoperative wound healing disorders oc-
curred, nor any postoperative fractures [31].
A statistically significant correlation was seen between
recurrence and use of adjuvant (P = 0.044) in a study byCummings et al. that evaluated the effectiveness of cur-
ettage with or without the use of an argon beam [30].
The authors did not observe any relapses in the group
treated with an adjuvant argon beam and no periopera-
tive or postoperative complications were seen. Another
evaluation of curettage surgery with an argon beam, by
Steffner et al., also reported a statistically significant cor-
relation between the risk of the recurrence and use of
the argon beam [29].
Where surgery is contradicted due to a difficult surgi-
cal approach, embolization [21,22] or percutaneous
sclerotherapy [23-25] can be an optional treatment: an-
other indication for embolization being a reduction in
operative blood loss that facilitates curettage, especially
in the pelvis or spine [26]. Both techniques can be used
in cases of postsurgical recurrence. Embolization is usu-
ally performed with use of polyvinyl alcohol, N-2-butyl
cyanoacrylate or Ethibloc® [36]. De Cristofaro et al. de-
scribed the treatment of 14 patients with ABC where
polyvinyl alcohol was used. Although embolization was
not possible in 5 of these patients due to lack of a
recognizable artery or common vascular supply to the
lesion and spinal column, the authors obtained almost
complete ossification in 11 cases, recurrences with
pathological fracture in 2 cases and an unchanged cyst
in 1 case, after a mean number of 2.3 procedures per pa-
tient. No complications were reported [21].
The most encouraging results can be seen in a paper
by Rossi et al., who indicated that arterial embolization
with cyanoacrylate may be the treatment of choice for
ABC because it is less invasive, cheaper and simpler than
surgery and is easily repeatable. The treatment was
found to be effective in 32 patients (94%) and complica-
tions were noticed only in 3 procedures, which were
cases of skin necrosis and transient paresis [22]. Al-
though recent studies show this treatment to have good
results, pulmonary embolism or ischemia of vital struc-
tures not related to the tumor can occur [37].
Another new procedure that is both simple and min-
imally invasive is the aforementioned percutaneous
sclerotherapy using a thrombogenic substance, which in-
duces an inflammatory reaction to a foreign body but
lacks osteogenic properties. The use of one such sub-
stance in ABC management, Ethibloc®, was first reported
by Adamsbaum et al., who achieved satisfactory healing
in two cases [38]. Other studies show that percutaneous
embolization may be considered a reliable alternative to
surgery but, due to possible complications, this therapy
is recommended only in deep located ABCs without
marked venous drainage. Guiband et al. treated 14 pa-
tients with ABCs with total lesion healing in 13 cases
(87%) and partial healing in 2 cases (13%), without re-
currences, the complications being 1 case of aseptic os-
teitis and a small pulmonary infarct [23]. Garg et al.,
Flont et al. World Journal of Surgical Oncology 2013, 11:109 Page 7 of 8
http://www.wjso.com/content/11/1/109who assessed the outcomes of CT-guided percutaneous
injection of Ethibloc® into ABCs in ten patients, obtained
total resolution of the lesion in seven patients and partial
response in three, with the only complication being an
aseptic abscess [24]. However, Topouchian et al.
reported a high rate of local and general complications
after Ethibloc® injection including one pulmonary em-
bolism and four aseptic fistulizations; the authors aban-
doned fibrosing agent injections in the treatment of
ABC [39]. In a comparison of sclerotherapy with curet-
tage in ABC treatment by Varshney et al., it was re-
ported that repetitive sclerotherapy using polidocanol is
a minimally invasive method that is safer than curettage,
although similar recurrence rates are noted for the two
treatment methods [25].
In the study group used in the present work, more
radical treatment methods than those presented in the
previous studies were used. En bloc excisions of bone
fragments were performed in as much as 40% of pa-
tients, especially in the case of an Enneking’s III central
lesion or expendable bones, which could be associated
with more frequent postoperative complications. In the
group of en bloc excision, only one complication oc-
curred, versus two complications in the curettage group.
In fact, it could not be demonstrated that bone fragment
excision was associated with more frequent postopera-
tive complications. Unfortunately, due to the small size
of the sample, this remains only a hypothesis. It should
also be noted that excision of a bone fragment and its
replacement with bone graft is technically more difficult,
more time consuming and often requires autograft bone
harvesting, therefore it is not a standard treatment.
Pain and ROM limitation on follow-up were more
common in the group where en bloc excision of bone
fragments was performed, but no statistically significant
differences between the procedures were found. All is-
sues reported by our patients were mild in nature and
occurred in rather non-specific situations, and although
they did not interfere with any of our patient’s daily ac-
tivities, they might impair athletic performance. More-
over, reduced ROM in this group applied usually to only
one plane. Furthermore, no significant intergroup differ-
ence was found in muscle strength assessment. However,
weakening of isometric muscle force in at least one
range was observed in as much as half of the patients in
the en bloc excision group: four patients in one plane,
and one in two planes. This may result from soft tissue
damage during an extensive procedure, from a patho-
logical fracture or from prolonged postoperative
immobilization in comparison with the curettage group.
Muscle force reduction in eight patients applied only to
one ROM plane, four from the curettage group and four
from the en bloc excision group. In the remaining two
patients, one in each treatment arm, the limitationapplied to two ROM planes, and exceeded 50% when
compared to the healthy side. Such disproportion ser-
iously affects the physical activity of the patient.
The weakness of our study is an insufficient number
of patients to draw statistically significant conclusions.
For this reason, we limited this paper to cohort descrip-
tion and to forming hypotheses that should be investi-
gated on larger patient samples. However, taking into
account the low annual incidence of primary ABC (0.14
per 100,000 individuals), building up a more numerous
study cohort would be a challenge [34].
Conclusions
Curettage is a standard procedure in ABC treatment. En
bloc excision is another option, more technically demand-
ing, that may be considered in recurrent lesions with ex-
tensive bone destruction or for cysts in an expendable
location.
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